Show simple item record

dc.contributor.author
Pradier, Melanie F.
dc.contributor.author
Reis, Bernhard
dc.contributor.author
Jukofsky, Lori
dc.contributor.author
Milletti, Francesca
dc.contributor.author
Ohtomo, Toshihiko
dc.contributor.author
Perez-Cruz, Fernando
dc.contributor.author
Puig, Oscar
dc.date.accessioned
2019-04-16T08:22:13Z
dc.date.available
2019-04-16T03:22:39Z
dc.date.available
2019-04-16T08:22:13Z
dc.date.issued
2019
dc.identifier.issn
1471-2407
dc.identifier.other
10.1186/s12885-019-5472-0
en_US
dc.identifier.uri
http://hdl.handle.net/20.500.11850/338187
dc.identifier.doi
10.3929/ethz-b-000338187
dc.description.abstract
Background Codrituzumab, a humanized monoclonal antibody against Glypican-3 (GPC3), which is expressed in hepatocellular carcinoma (HCC), was tested in a randomized phase II trial in advanced HCC patients who had failed prior systemic therapy. Biomarker analysis was performed to identify a responder population that benefits from treatment. Methods A novel statistical method based on the Indian buffet process (IBP) was used to identify biomarkers predictive of response to treatment with Codrituzumab. The IBP is a novel method that allows flexibility in analysis design, and which is sensitive to slight, but meaningful between-group differences in biomarkers in very complex datasets Results The IBP model identified several subpopulations of patients having defined biomarker values. Tumor necrosis and viable cell content in the tumor were identified as prognostic markers of disease progression, as were the well-known HCC prognostic markers of disease progression, alpha-fetoprotein and Glypican-3 expression. Predictive markers of treatment response included natural killer (NK) cell surface markers and parameters influencing NK cell activity, all related to the mechanism of action of this drug Conclusions The Indian buffet process can be effectively used to detect statistically significant signals with high sensitivity in complex and noisy biological data
en_US
dc.format
application/pdf
en_US
dc.language.iso
en
en_US
dc.publisher
BioMed Central
en_US
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject
Codrituzumab
en_US
dc.subject
Indian buffet process
en_US
dc.subject
Natural killer cells
en_US
dc.title
Case-control Indian buffet process identifies biomarkers of response to Codrituzumab
en_US
dc.type
Journal Article
dc.rights.license
Creative Commons Attribution 4.0 International
dc.date.published
2019-03-28
ethz.journal.title
BMC Cancer
ethz.journal.volume
19
en_US
ethz.journal.abbreviated
BMC cancer (Online)
ethz.pages.start
278
en_US
ethz.size
7 p.
en_US
ethz.version.deposit
publishedVersion
en_US
ethz.identifier.wos
ethz.identifier.scopus
ethz.publication.place
London
en_US
ethz.publication.status
published
en_US
ethz.date.deposited
2019-04-16T03:22:40Z
ethz.source
WOS
ethz.eth
yes
en_US
ethz.availability
Open access
en_US
ethz.rosetta.installDate
2019-04-16T08:22:56Z
ethz.rosetta.lastUpdated
2019-04-16T08:22:56Z
ethz.rosetta.exportRequired
true
ethz.rosetta.versionExported
true
ethz.COinS
ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.atitle=Case-control%20Indian%20buffet%20process%20identifies%20biomarkers%20of%20response%20to%20Codrituzumab&rft.jtitle=BMC%20Cancer&rft.date=2019&rft.volume=19&rft.spage=278&rft.issn=1471-2407&rft.au=Pradier,%20Melanie%20F.&Reis,%20Bernhard&Jukofsky,%20Lori&Milletti,%20Francesca&Ohtomo,%20Toshihiko&rft.genre=article&
 Search via SFX

Files in this item

Thumbnail

Publication type

Show simple item record